Drug Trial Radar · NCT06475742
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
680
Planned (sponsor's estimate)
Start
Jul 30, 2024
Primary completion
Sep 2032
Study completion Sep 2032
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus. * How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for up to 5 years. Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year. In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for up to 5 years.
Conditions
- Lupus Erythematosus, Systemic
Interventions
CenerimodDrug
Film-coated tablets at a dose of 4 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse eventsTime frame: Day 1 (post dose) to a maximum of 5.5 years
- Serious adverse eventsTime frame: Day 1 (post dose) to a maximum of 5.5 years
- Adverse events of special interestTime frame: Day 1 (post dose) to a maximum of 5.5 years
Locations
122 sites in 26 countries. Site status is shown where the registry gives one.
University of Colorado Denver
Aurora, Colorado
Clinical Research of West Florida, Inc.
Clearwater, Florida
Omega Research MetroWest, LLC
DeBary, Florida
SouthCoast Research Center, Inc.
Miami, Florida
Allied Biomedical Research Institute
Miami, Florida
D&H National Research Centers INC
Miami, Florida
Professional research Center INC
Miami, Florida
San Marcus Res Clin Inc.
Miami Lakes, Florida
Accurate Clinical Research Inc. - Lake Charles
Lake Charles, Louisiana
RB Wellness Clinic
Las Vegas, Nevada
Accurate Clinical Research Inc - (Najam)
Baytown, Texas
Novel Research LLC
Bellaire, Texas
Accurate Clinical Research Inc.
Houston, Texas
Sun Research
San Antonio, Texas
Aprillus Asistencia e Investigacion
Buenos Aires, Argentina
Centro Médico Arsema
Buenos Aires, Argentina
Fundación Respirar
Buenos Aires, Argentina
IR Medical Center S.A.
Mendoza, Argentina
Instituto Medico CER
Quilmes, Argentina
Instituto CAICI SRL
Rosario, Argentina
Centro de investigaciones medicas Tucuman
San Miguel de Tucumán, Argentina
ICT (Investigaciones Clínicas Tucumán)
San Miguel de Tucumán, Argentina
LMK Servicos Medico S/S
Porto Alegre, Brazil
SER - Serviços Especializados em Reumatologia da Bahia
Salvador, Brazil
Outpatient Clinic for Specialized Outpatient Medical Care - Medical Center Kyuchuk Parizh Ltd.
Plovdiv, Bulgaria
DCC Equita EOOD
Varna, Bulgaria
Enroll SpA
Providencia, Chile
Biomedica Research Group
Providencia, Chile
Sociedad Médica del Aparato Locomotor S. A.
Providencia, Chile
Centro de Especialidades Medicas Vanguardia
Temuco, Chile
Clinical Research Chile SpA
Valdivia, Chile
Hospital San José de Victoria
Victoria, Chile
Clínica de la costa S.A.S.
Barranquilla, Colombia
IDEARG (Instituto de Enfermedades Autoinmunes Renato Guzmán)
Bogotá, Colombia
Servimed S.A.S
Bucaramanga, Colombia
Centro de Estudios de Reumatología y Dermatología
Cali, Colombia
Preventive Care SAS
Chía, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Healthy Medical Center SAS
Zipaquirá, Colombia
iMedica s.r.o.
Brno, Czechia
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.